HAIC plus immunotherapy and targeted therapy before surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining two drugs (adebrelimab and lenvatinib) with a liver-directed chemotherapy infusion (HAIC) to shrink locally advanced bile duct or gallbladder cancers enough to allow surgery. It is for people who haven't had prior treatment for their biliary cancer and whose cancer has not spread far.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of bile duct or gallbladder cancer that is locally advanced and might be removable with surgery.
- Your cancer has not spread to the lining of your abdomen or other distant parts.
- You have not had any prior systemic treatment (like chemotherapy) for this cancer.
- You are in good overall health (ECOG score 0 or 1) and your liver function is adequate (Child-Pugh score 7 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.